PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: FTPB (French Technology Press Bureau)

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

IN CELL ART and Sanofi Pasteur Enter into Research Collaboration Agreement - IN CELL ART, a biotechnology company involved in macromolecular drug (siRNA, DNA, proteins) delivery systems, has announced that the company has entered into a research collaboration agreement with Sanofi Pasteur
IN CELL ART and Sanofi Pasteur Enter into Research Collaboration Agreement

 

NewswireToday - /newswire/ - London, United Kingdom, 2008/09/09 - IN CELL ART, a biotechnology company involved in macromolecular drug (siRNA, DNA, proteins) delivery systems, has announced that the company has entered into a research collaboration agreement with Sanofi Pasteur.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

IN CELL ART, announced that the company has entered into a research collaboration agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, to evaluate IN CELL ART nanocarriers’ technologies in the context of Sanofi Pasteur’s vaccines programme. Convincing results arising from such studies should lead to the continuation of IN CELL ART nanocarriers’ evaluation in Sanofi Pasteur’s new vaccines development.

IN CELL ART offers a range of biotechnology development services. The French company has expertise in antibody generation using genetic immunisation, allowing for the rapid synthesis of antibodies to any gene-specific antigen. This technology is particularly suitable for screening applications, which lead to the identification of antibodies of therapeutic interest.

IN CELL ART is also pursuing highly promising approaches in the field of DNA-based therapeutic and prophylactic vaccines, with successful studies in animal models of cancers and infectious diseases. IN CELL ART works in partnership with pharmaceutical and biotechnology companies and grants licences for its vaccine formulation.

With ongoing R&D programmes in the fields of oncology, as well as cardiovascular and anti-infectious diseases, IN CELL ART also works closely with companies that are active in the development of RNAi therapeutic products for interference with the expression of targeted disease-associated genes. Besides, IN CELL ART works with companies involved in the development of therapeutic proteins for the improvement of pharmacokinetics. In both these areas, IN CELL ART grants licences for its nanocarriers.

Finally, IN CELL ART is commercializing ICAFectin®441 and ICAFectin®442, which are DNA and siRNA transfection reagents for primary and stem cells.

About IN CELL ART

IN CELL ART (incellart.com), which is headquartered in Nantes (in western France), is a biopharmaceutical company specialising in the preclinical and pharmaceutical development of nanocarriers for macromolecular drugs. Its founder and research team, which includes a Nobel Laureate, have designed new classes of vectors that are organised on a nanometric scale, which enables them to cross the cell barrier efficiently and safely.

IN CELL ART is a privately held company, which was founded in 2005. It is a member of the Atlantic Biotherapies high-tech cluster of biotechnology companies in western France.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: FTPB (French Technology Press Bureau)

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


IN CELL ART and Sanofi Pasteur Enter into Research Collaboration Agreement

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Kate Ambler - UBIFRANCE.fr 
+44(0)20 7235 5330 contact.ftpb[.]ubifrance.fr
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any FTPB (French Technology Press Bureau) securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From FTPB (French Technology Press Bureau) / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)